Participated · Series A · Jun 2026

Syntax Bio develops a CRISPR-based Cellgorithm™ platform intended to program and accelerate stem cell differentiation to enable scalable cell therapies. The company is advancing a pancreatic beta cell therapy candidate for type 1 diabetes and plans to fund preclinical proof-of-concept studies with proceeds from its expanded Series A. Syntax Bio has publicly reported a collaboration with Mayo Clinic, received a grant from Breakthrough T1D, and published peer-reviewed research in Science Advances describing its technology. Financially, the company expanded its Series A to $14.4 million, bringing total funding to over $25 million. Leadership changes accompanying the financing include a CEO who joined in 2025 and new executive, board, and scientific advisory appointments to support translational development and commercialization. The company positions its platform as a way to replace slow, labor-intensive differentiation processes with a programmable approach to generate functional cells at scale.

Participated · Series A · May 2026

Latus Bio develops a gene therapy platform that pairs proprietary and engineered AAV capsids with clinically optimized routes of administration to enable efficient delivery at low doses. The company’s two lead programs are LTS-101 for CLN2 disease, which has IND clearance and multiple FDA designations, and LTS-201 for Huntington’s disease, which is being prepared for IND submission. Latus is advancing capsid variants for potential application beyond CNS disorders, including kidney, eye, heart, and muscle diseases. Management emphasizes scalability and lower-dose delivery to improve safety, manufacturability, and cost, targeting larger rare and broader CNS indications. The company raised $97 million in its Series A (including a $43 million extension) to fund operations through key clinical milestones for these programs.

Participated · Series B · Apr 2026

Sidewinder Therapeutics is focused on engineering next-generation bispecific ADCs that target tumor-specific receptor co-complexes to enhance tumor specificity and internalization. The company’s pipeline targets indications including squamous cell carcinomas of the lung and head and neck and gastrointestinal cancers such as colorectal cancer. Sidewinder was founded in 2023 and is headquartered in San Diego. It has partnered with Lonza to apply Synaffix’s site-specific linker‑payload platform across multiple programs. The company plans to advance its lead program into clinical development in 2027. Financially, Sidewinder has raised a total of $162 million following the $137 million Series B.

Led · Series B · Mar 2026

AgZen develops RealCoverage, a system that measures how much spray reaches leaf surfaces in real time and provides actionable recommendations to improve spray targeting. Its sensors detect droplets as small as 150 microns, capture data every few inches, and operate at sprayer speeds up to 18 miles per hour. Led by CEO Vishnu Jayaprakash, the company has sold out its 2026 production allocation. Following the Series B, AgZen plans to accelerate product development. The company also announced a partnership with Syngenta AG and received a strategic investment from Syngenta Group Ventures. No revenue or user metrics were disclosed in the article.

Led · Series A · Oct 2025

Nilo Therapeutics is a biotechnology startup leveraging discoveries at the nexus of neuroscience and immunology to create therapeutics that centrally modulate immune responses. Its lead concept targets vagal neurons that orchestrate systemic inflammation, offering an alternative to broad immunosuppression by restoring immune homeostasis through coordinated pathway control. This approach is intended to reduce therapeutic resistance and unlock treatment options across a wide range of autoimmune and inflammatory disorders with high unmet need. The science originates from founders Charles Zuker (Columbia), Ruslan Medzhitov (Yale), and Steve Liberles (Harvard) and was incubated with The Column Group. Fresh out of stealth, the company is building laboratories in New York City and expanding an interdisciplinary R&D team. A $101 million Series A financing will fund these efforts and advance the company’s preclinical programs. Nilo has not yet disclosed commercial products, revenue, or user metrics.